Savara Inc SEC Filings

Savara Inc. (SVRA) launched a primary offering of 23,809,524 shares of common stock and pre-funded warrants to purchase 7,142,857 shares. The shares are priced at $4.20 and the pre-funded warrants at $4.199 with a $0.001 exercise price. Gross proceeds are $129,992,857, with underwriting discounts of $7,800,000, for net proceeds before expenses of $122,192,857. The company estimates net proceeds of about $121.7 million after expenses.

The underwriters have a 30‑day option to buy up to 4,642,857 additional shares; if fully exercised, net proceeds before expenses would be $140,522,857. Savara plans to use the funds for working capital and general corporate purposes, including advancing MOLBREEVI toward regulatory approval, building commercialization infrastructure and supply, and launch preparation in the U.S. and EU.

The company also disclosed a purchase and sale agreement with RTW Investments under which Savara would receive $75.0 million upon FDA approval of MOLBREEVI on or before March 31, 2027, in exchange for tiered royalties on U.S. net sales, capped at $187.5 million.

Savara Inc. announced an underwritten offering, agreeing to issue and sell 23,809,524 shares of common stock at $4.20 per share and pre-funded warrants to purchase 7,142,857 shares with a $0.001 exercise price, priced at $4.199 per warrant. The company also granted the underwriters a 30‑day option to purchase up to an additional 4,642,857 shares at the public offering price, less underwriting discounts and commissions.

The transaction was conducted under Savara’s effective Form S-3 shelf, with closing expected on October 31, 2025, subject to customary conditions. Jefferies LLC and Piper Sandler & Co. acted as representatives of the several underwriters. Legal opinions related to the issuance were provided by Polsinelli PC.

Savara Inc. (SVRA) launched a primary offering of common stock and pre-funded warrants under a preliminary prospectus supplement. The company may sell common shares and, for certain existing large investors, pre-funded warrants with a $0.001 per-share exercise price. SVRA’s stock last closed at $4.41 on Nasdaq. The underwriters have a 30‑day option to purchase additional shares. Proceeds are intended for working capital and general corporate purposes, including MOLBREEVI clinical, regulatory, manufacturing, and U.S./EU launch preparations.

As context, shares outstanding were 172,836,922 as of June 30, 2025; this is a baseline figure, not the amount being offered. Pre-funded warrants are exercisable at any time, include 9.99% (up to 19.99% with notice) ownership limits, and will not be listed.

Recent development: SVRA entered a purchase and sale agreement with funds managed by RTW Investments, LP for $75.0 million payable upon FDA approval of MOLBREEVI on or before March 31, 2027, in exchange for tiered U.S. sales royalties ranging from 7.0% to 1.0% (with a 9.5% tier if a prior-year threshold is not met) until the Purchaser receives $187.5 million. A portion of the payment must repay outstanding indebtedness, and the agreement includes customary covenants and a lien on specified IP assets at closing.

Savara Inc. (SVRA) entered a royalty financing with RTW Investments. The Purchaser will pay $75 million to Savara upon FDA approval of MOLBREEVI for autoimmune PAP on or before March 31, 2027, subject to customary closing conditions. In return, RTW receives a true sale of assigned interests, including tiered U.S. Net Sales royalties on MOLBREEVI ranging from 7.0% to 1.0%, with the 7.0% tier rising to 9.5% in a calendar year if the prior year’s Net Sales fall below a specified level, until RTW has received up to $187.5 million in total payments.

Royalties begin in the first calendar quarter of U.S. commercial sales. Savara expects the effective royalty rate over the life of the agreement to be in the low single digits. The agreement includes a buy‑back option tied to certain changes of control within two years of receiving the purchase price, and requires using a portion of proceeds to repay outstanding indebtedness unless otherwise agreed. Savara also disclosed a putative securities class action filed on September 8, 2025 related to public statements on MOLBREEVI; the company intends to defend the case.

Savara Inc. (SVRA) Form 4: The company’s Chief Medical Officer reported equity awards on 10/20/2025. The filing shows an acquisition of 35,000 restricted stock units (RSUs) at a price of $0.00, lifting directly held common shares to 190,000 following the transaction. The RSUs vest in full on 10/17/2027, each converting into one share upon vesting.

Separately, the officer received a stock option for 70,000 shares with an exercise price of $4.11 and an expiration on 10/20/2035. This option vests in sixteen equal quarterly installments beginning 10/17/2025. These are routine compensatory awards and do not indicate open‑market buying or selling.

Savara Inc (SVRA) reported an insider ownership update as its Chief Medical Officer filed a Form 3. The filing lists 155,000 shares of common stock beneficially owned, noted to include RSUs that vest in full on December 4, 2025 (80,000) and December 12, 2026 (75,000), each representing a right to one share upon vesting.

Derivative holdings include stock options for 110,000 shares at $4.13 expiring December 11, 2033, vesting in sixteen equal quarterly installments from December 4, 2023, and options for 175,000 shares at $3.35 expiring December 12, 2034, vesting in sixteen equal quarterly installments from December 12, 2024.

Frazier-affiliated investment vehicles disclosed shared voting and dispositive power over specified Savara Inc. (SVRA) common stock positions. Frazier Life Sciences Public Fund, L.P. directly holds 6,745,296 shares (3.9%); Frazier Life Sciences Public Overage Fund, L.P. holds 2,889,469 shares (1.7%); Frazier Life Sciences X, L.P. holds 324,346 shares (0.2%); and Frazier Life Sciences XI, L.P. holds 1,503,190 shares (0.9%). These percentages are calculated using 172,836,922 shares outstanding as reported by the issuer. The filing clarifies that certain investment committees act by majority vote and explicitly corrects prior attributions of beneficial ownership to individual committee members.

Savara Inc. reported widening losses as it advances its sole product candidate, MOLBREEVI, an inhaled GM-CSF for autoimmune pulmonary alveolar proteinosis. Net loss was $30.4 million for the quarter and $57.0 million for the six months, up from $22.2 million and $42.6 million a year earlier, driven by higher research-and-development and commercial-preparation costs.

The company holds $17.4 million in cash and $129.0 million in short-term investments (total ~$146.4 million) and states this is sufficient to fund operations for at least the next 12 months. Savara received an FDA Refusal to File for its BLA but says the RTF raised CMC information requests only, not safety or efficacy; the company plans a December resubmission and will request Priority Review. Savara has a $200 million Hercules term loan facility with an initial $30 million draw, conditional future tranches tied to regulatory and revenue milestones and covenanted cash requirements that could restrict liquidity.